Table 1.
Correlation between DUSP4 expression and clinicopathological characteristics in PTC in the FUSCC and TCGA cohorts
| Variables | FUSCC cohort (N=120)
|
TCGA cohort (N=499)
|
||||||
|---|---|---|---|---|---|---|---|---|
| N | Low | High | P-value | N | Low | High | P-value | |
| Sex | 0.242 | 0.075 | ||||||
| Male | 29 | 12 (41.4%) | 17 (58.6%) | 136 | 77 (56.6%) | 59 (43.4%) | ||
| Female | 91 | 49 (53.8%) | 42 (46.2%) | 363 | 173 (47.7%) | 190 (52.3%) | ||
| Age (years) | 0.584 | 0.503 | ||||||
| <45 | 60 | 29 (48.3%) | 31 (51.7%) | 229 | 111 (48.5%) | 118 (51.5%) | ||
| ≥45 | 60 | 32 (53.3%) | 28 (46.7%) | 270 | 139 (51.5%) | 131 (48.5%) | ||
| Maximum size of tumor (cm) | 0.733 | 0.250 | ||||||
| ≤2 | 99 | 51 (51.5%) | 48 (48.5%) | 85 | 50 (58.8%) | 35 (41.2%) | ||
| 2–4 | 18 | 8 (44.4%) | 10 (55.6%) | 131 | 73 (55.7%) | 58 (44.3%) | ||
| >4 | 3 | 2 (66.7%) | 1 (33.3%) | 131 | 63 (48.1%) | 68 (51.9%) | ||
| Multifocality | 0.458 | 0.225 | ||||||
| Unifocal | 91 | 48 (52.7%) | 43 (47.3%) | 263 | 124 (47.1%) | 239 (52.9%) | ||
| Multifocal | 29 | 13 (44.8%) | 16 (55.2%) | 226 | 119 (52.7%) | 107 (47.3%) | ||
| Histological type | 0.981 | 0.901 | ||||||
| Classical PTC | 118 | 60 (50.8%) | 58 (49.2%) | 357 | 181 (50.7%) | 176 (49.3%) | ||
| Follicular PTC | 2 | 1 (50.0%) | 1 (50.0%) | 96 | 45 (46.9%) | 51 (53.1%) | ||
| Tall-cell PTC | – | – | – | 37 | 19 (51.4%) | 18 (48.6%) | ||
| Other types | – | – | – | 9 | 5 (55.6%) | 4 (44.4%) | ||
| Coexistent HT | 0.886 | 0.058 | ||||||
| Yes | 23 | 12 (52.2%) | 11 (47.8%) | 35 | 12 (34.3%) | 23 (65.7%) | ||
| No | 97 | 49 (50.5%) | 48 (49.5%) | 406 | 207 (51.0%) | 199 (49.0%) | ||
| ETE | 0.023* | 0.024* | ||||||
| Yes | 11 | 2 (18.2%) | 9 (81.8%) | 153 | 65 (42.5%) | 88 (57.5%) | ||
| No | 109 | 59 (54.1%) | 50 (45.9%) | 329 | 176 (53.5%) | 153 (46.5%) | ||
| LNM | 0.006* | 0.003* | ||||||
| N0 | 42 | 29 (69.0%) | 13 (31.0%) | 226 | 128 (56.6%) | 98 (43.4%) | ||
| N1 | 77 | 33 (42.9%) | 44 (57.1%) | 223 | 95 (42.6%) | 128 (57.4%) | ||
| Nx | 1 | 50 | ||||||
| T stage | 0.076 | 0.132 | ||||||
| T1–T2 | 106 | 57 (53.8%) | 49 (46.2%) | 307 | 162 (52.8%) | 145 (47.2%) | ||
| T3–T4 | 14 | 4 (28.6%) | 10 (71.4%) | 192 | 88 (45.8%) | 104 (54.2%) | ||
| TNM stage | 0.547 | 0.005* | ||||||
| I | 92 | 50 (54.3%) | 42 (45.7%) | 284 | 148 (52.1%) | 136 (47.9%) | ||
| II | 3 | 1 (33.3%) | 2 (66.7%) | 53 | 34 (64.2%) | 19 (35.8%) | ||
| III | 16 | 6 (37.5%) | 10 (62.5%) | 108 | 51 (47.2%) | 57 (52.8%) | ||
| IV | 9 | 4 (44.4%) | 5 (55.6%) | 54 | 17 (31.5%) | 37 (68.5%) | ||
| BRAFV600E | 0.002* | <0.001* | ||||||
| Mutation | 57 | 21 (36.8%) | 36 (63.2%) | 249 | 93 (37.3%) | 156 (62.7%) | ||
| Wild-type | 63 | 41 (65.1%) | 22 (34.9%) | 167 | 113 (67.7%) | 54 (32.3%) | ||
Note:
*
Statistically significant.
Abbreviations: DUSP4, dual specificity phosphatase 4; PTC, papillary thyroid cancer; FUSCC, Fudan University Shanghai Cancer Center; TCGA, The Cancer Genomics Atlas; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; LNM, lymph node metastasis; Nx, evaluation not available; TNM, tumor–node–metastasis.